Accéder directement au contenu Accéder directement à la navigation
Article dans une revue

Effect of Statin Therapy on Mortality in Patients With Ventilator-Associated Pneumonia: a randomized clinical trial

Abstract : Importance: Observational studies have reported that statin use may be associated with improved outcomes of various infections. Ventilator-associated pneumonia (VAP) is the most common infection in the intensive care unit (ICU) and is associated with substantial mortality. Objective: To determine whether statin therapy can decrease day-28 mortality in patients with VAP. Design, setting, and participants: Randomized, placebo-controlled, double-blind, parallel-group, multicenter trial performed in 26 intensive care units in France from January 2010 to March 2013. For power to detect an 8% absolute reduction in the day-28 mortality rate, we planned to enroll 1002 patients requiring invasive mechanical ventilation for more than 2 days and having suspected VAP, defined as a modified Clinical Pulmonary Infection Score of 5 or greater. The futility stopping rules were an absolute increase in day-28 mortality of at least 2.7% with simvastatin compared with placebo after enrollment of the first 251 patients. Interventions: Participants were randomized to receive simvastatin (60 mg) or placebo, started on the same day as antibiotic therapy and given until ICU discharge, death, or day 28, whichever occurred first. Main outcomes and measures: Primary outcome was day-28 mortality. Day-14, ICU, and hospital mortality rates were determined, as well as duration of mechanical ventilation and Sequential Organ Failure Assessment (SOFA) scores on days 3, 7, and 14. Results: The study was stopped for futility at the first scheduled interim analysis after enrollment of 300 patients, of whom all but 7% in the simvastatin group and 11% in the placebo group were naive to statin therapy at ICU admission. Day-28 mortality was not lower in the simvastatin group (21.2% [95% CI, 15.4% to 28.6%) than in the placebo group (15.2% [95% CI, 10.2% to 22.1%]; P = .10; hazard ratio, 1.45 [95% CI, 0.83 to 2.51]); the between-group difference was 6.0% (95% CI, -3.0% to 14.9%). In statin-naive patients, day-28 mortality was 21.5% (95% CI, 15.4% to 29.1%) with simvastatin and 13.8% (95% CI, 8.8% to 21.0%) with placebo (P = .054) (between-group difference, 7.7% [95%CI, -1.8% to 16.8%). There were no significant differences regarding day-14, ICU, or hospital mortality rates; duration of mechanical ventilation; or changes in SOFA score. Conclusions and relevance: In adults with suspected VAP, adjunctive simvastatin therapy compared with placebo did not improve day-28 survival. These findings do not support the use of statins with the goal of improving VAP outcomes. Trial registration: clinicaltrials.gov Identifier: NCT01057758.
Liste complète des métadonnées

https://hal.umontpellier.fr/hal-02549165
Contributeur : Emilie Passerieux <>
Soumis le : mardi 21 avril 2020 - 11:32:44
Dernière modification le : vendredi 15 mai 2020 - 12:22:09

Lien texte intégral

Identifiants

Collections

Citation

Laurent Papazian, Antoine Roch, Pierre Emmanuel Charles, Christine Penot-Ragon, Gilles Perrin, et al.. Effect of Statin Therapy on Mortality in Patients With Ventilator-Associated Pneumonia: a randomized clinical trial. JAMA Cardiology, American Medical Association 2013, 310 (16), pp.1692. ⟨10.1001/jama.2013.280031⟩. ⟨hal-02549165⟩

Partager

Métriques

Consultations de la notice

12